Double-Blind, Placebo-Controlled Randomized Trial of Epicutaneous Immunotherapy in Children of Milk-Induced Eosinophilic Esophagitis - 05/02/19
Doi : 10.1016/j.jaci.2018.12.974
Jonathan M. Spergel, Dr.MD PhD FAAAAI 1, Okan Elci 2, Amanda Muir, Dr.MD 3, Chris A. Liacouras, Dr.MD 4, Benjamin Wilkins 2, Deirdre D. Burke, Ms.CRC 5, Megan Ott Lewis, Ms.MSN CRNP 5, Terri F. Brown-Whitehorn, Dr.MD FAAAAI 5, Antonella Cianferoni, Dr.MD PhD FAAAAI 6
1 Perelman School of Medicine at Univ of Pennsylvania, Philadelphia, PA
2 The Children's Hospital of Philadelphia, Philadelphia
3 Children's Hospital Of Philadelphia - Gastroenterology, Philadelphia, PA
4 Children's Hospital of Philadelphia, Exton, PA
5 Children's Hospital of Philadelphia, Philadelphia, PA
6 The Children's Hospital of Philadelphia, Philadelphia, PA
L30
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2018
Pubblicato da Elsevier Masson SAS.
Vol 143 - N° 2S
P. AB430 - febbraio 2019 Ritorno al numero
Articolo precedente
- Omalizumab Treatment Patterns in Chronic Idiopathic Urticaria (CIU): Evidence from a Large Allergy Practice in the United States (US)
- Brian D. Stone, Abhishek Kavati, Maryia Zhdanava, Benjamin Ortiz, Jason Lecocq, Bradd Schiffman, Hoi Ching Cheung, Patrick Lefebvre
- Safety and Tolerability of a Novel Peptide-Based Immunotherapy for Peanut Allergy
- Sara R. Prickett, Pascal LC. Hickey, Judy Bingham, Tracy Phan, Jodie Abramovitch, Jennifer M. Rolland, William B. Smith, Mark Hew, Robyn E.O. Hehir
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?